Australasian Biospecimen Network-Oncology

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Tibor A Zwimpfer, Sian Fereday, Ahwan Pandey, Dinuka Ariyaratne, Madawa W Jayawardana, Laura Twomey, Céline M Laumont, Catherine J Kennedy, Adelyn Bolithon, Nicola S Meagher, Katy Milne, Phineas Hamilton, Jennifer Alsop, Antonis C Antoniou, George Au-Yeung, Matthias W Beckmann, Amy Berrington de Gonzalez, Christiani Bisinotto, Freya Blome, Clara Bodelon

2026-04-01

BRCA-associated homologous recombination deficiency (HRD) is present in ~50% of high-grade serous carcinomas (HGSC) and predicts s..

Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome

SS Manda, MM Espersen, C Mapagu, N Bouantoun, J Boros, YE Chiew, S Srirangan, S Pattnaik, CJ Kennedy, AH Brand, DW Garsed, A Pandey, DDL Bowtell, N Lucas, D Xavier, S Mahboob, D Bucio-Noble, B Tully, PG Hains, PJ Robinson

2025-12-01

Improved biomarkers of treatment response are needed for patients with high-grade serous ovarian cancer (HGSC). A challenge is sub..

Federated Deep Learning Enables Cancer Subtyping by Proteomics

Z Cai, EL Boys, Z Noor, AT Aref, D Xavier, N Lucas, SG Williams, JMS Koh, RC Poulos, Y Wu, M Dausmann, KL Mackenzie, A Aguilar-Mahecha, C Armengol, MM Barranco, M Basik, ED Bowman, R Clifton-Bligh, EA Connolly, WA Cooper

2025-09-01

Artificial intelligence applications in biomedicine face major challenges from data privacy requirements. To address this issue fo..

Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer

EM Dicks, JP Tyrer, S Ezquina, M Jones, J Baierl, PC Peng, M Diaz, E Goode, SJ Winham, T Dörk, TV Gorp, AD Fazio, DDL Bowtell, DW Garsed, K Odunsi, K Moysich, M Pavanello, F Fostira, PM Webb, J Soukupová

2025-03-01

Rare, germline loss-of-function variants in a handful of DNA repair genes are associated with epithelial ovarian cancer. The aim o..

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer

BH Nelson, P Hamilton, MT Phung, K Milne, B Harris, S Thornton, D Stevens, S Kalaria, K Singh, CM Laumont, E Moss, A Alimujiang, NS Meagher, A Bolithon, S Fereday, CJ Kennedy, J Hendley, D Ariyaratne, K Alsop, N Traficante

2024-12-16

BACKGROUND. Despite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma ..

Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

D Ramachandran, JP Tyrer, S Kommoss, A DeFazio, MJ Riggan, PM Webb, PA Fasching, D Lambrechts, MJ García, C Rodríguez-Antona, MT Goodman, F Modugno, KB Moysich, BY Karlan, J Lester, SK Kjaer, A Jensen, E Høgdall, EL Goode, WA Cliby

2024-12-01

Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses ..

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

FAM Saner, K Takahashi, T Budden, A Pandey, D Ariyaratne, TA Zwimpfer, NS Meagher, S Fereday, L Twomey, KI Pishas, T Hoang, A Bolithon, N Traficante, K Alsop, EL Christie, EY Kang, GS Nelson, P Ghatage, CH Lee, MJ Riggan

2024-08-15

Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occu..

Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.

Flurina AM Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A Zwimpfer, Nicola S Meagher, Sian Fereday, Laura Twomey, Kathleen I Pishas, Therese Hoang, Adelyn Bolithon, Nadia Traficante, Kathryn Alsop, Elizabeth L Christie, Eun-Young Kang, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan

2023-11-10

BACKGROUND: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which ..

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

M Köbel, EY Kang, A Weir, PF Rambau, CH Lee, GS Nelson, P Ghatage, NS Meagher, MJ Riggan, J Alsop, MS Anglesio, MW Beckmann, C Bisinotto, M Boisen, J Boros, AH Brand, A Brooks-Wilson, ME Carney, P Coulson, M Courtney-Brooks

2023-05-01

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovari..

Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma

C Wang, MS Block, JM Cunningham, ME Sherman, BM McCauley, SM Armasu, RA Vierkant, N Traficante, A Talhouk, SJ Ramus, N Pejovic, M Kobel, BD Jorgensen, DW Garsed, S Fereday, JA Doherty, D Ariyaratne, MS Anglesio, M Widschwendter, T Pejovic

2023-04-10

Background: Better understanding of prognostic factors in tuboovarian high-grade serous carcinoma (HGSC) is critical, as diagnosis..

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Eun-Young Kang, Ashley Weir, Nicola S Meagher, Kyo Farrington, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan, Adelyn Bolithon, Gordana Popovic, Betty Leung, Katrina Tang, Neil Lambie, Joshua Millstein, Jennifer Alsop, Michael S Anglesio, Beyhan Ataseven, Ellen Barlow, Matthias W Beckmann, Jessica Berger

2023-03-01

Background: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma ..

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Ashley Weir, Eun-Young Kang, Nicola S Meagher, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S Anglesio, Matthias W Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H Brand, James D Brenton, Angela Brooks-Wilson

2023-01-26

Background: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (H..

Profiling the immune landscape in mucinous ovarian carcinoma

NS Meagher, P Hamilton, K Milne, S Thornton, B Harris, A Weir, J Alsop, C Bisinoto, JD Brenton, A Brooks-Wilson, DS Chiu, KL Cushing-Haugen, S Fereday, DW Garsed, SA Gayther, A Gentry-Maharaj, B Gilks, M Jimenez-Linan, CJ Kennedy, ND Le

2023-01-01

Objective: Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherap..

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

NS Meagher, KL Gorringe, M Wakefield, A Bolithon, CNI Pang, DS Chiu, MS Anglesio, KA Mallitt, JA Doherty, HR Harris, JM Schildkraut, A Berchuck, KL Cushing-Haugen, K Chezar, A Chou, A Tan, J Alsop, E Barlow, MW Beckmann, J Boros

2022-12-15

Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid ..

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

DW Garsed, A Pandey, S Fereday, CJ Kennedy, K Takahashi, K Alsop, PT Hamilton, J Hendley, YE Chiew, N Traficante, P Provan, D Ariyaratne, G Au-Yeung, NW Bateman, L Bowes, A Brand, EL Christie, JM Cunningham, M Friedlander, B Grout

2022-12-01

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after d..

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8( ) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas

Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, Pauline Kramer, Evan S Cairns, Derek S Chiu, Samuel CY Leung, Eun Young Kang, Nicola S Meagher, Catherine J Kennedy, Jessica Boros, Friedrich Kommoss, Hans-Walter Vollert, Florian Heitze, Andreas du Bois, Philipp Harter, Marcel Grube, Bernhard Kraemer, Annette Staebler, Felix KF Kommoss

2022-04-01

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is cons..

Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer

MCJ Quinn, K McCue, W Shi, SE Johnatty, J Beesley, A Civitarese, TA O'Mara, DM Glubb, JP Tyrer, SM Armasu, JS Ong, P Gharahkhani, Y Lu, B Gao, AM Patch, PA Fasching, MW Beckmann, D Lambrechts, I Vergote, DR Velez Edwards

2021-09-01

Background: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is co..

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer

H Song, EM Dicks, J Tyrer, M Intermaggio, G Chenevix-Trench, DD Bowtell, N Traficante, A Group, J Brenton, T Goranova, K Hosking, A Piskorz, E Van Oudenhove, J Doherty, HR Harris, MA Rossing, M Duerst, T Dork, NV Bogdanova, F Modugno

2021-05-01

Purpose The known epithelial ovarian cancer (EOC) susceptibility genes account for less than 50% of the heritable risk of ovarian ..

Strategies to enable large-scale proteomics for reproducible research

RC Poulos, PG Hains, R Shah, N Lucas, D Xavier, SS Manda, A Anees, JMS Koh, S Mahboob, M Wittman, SG Williams, EK Sykes, M Hecker, M Dausmann, MA Wouters, K Ashman, J Yang, PJ Wild, A deFazio, RL Balleine

2020-12-01

Reproducible research is the bedrock of experimental science. To enable the deployment of large-scale proteomics, we assess the re..

ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer

M Jung, J Gao, L Cheung, A Bongers, K Somers, M Clifton, EE Ramsay, AJ Russell, E Valli, AJ Gifford, J George, CJ Kennedy, MJ Wakefield, M Topp, GY Ho, CL Scott, DD Bowtell, A deFazio, MD Norris, M Haber

2020-10-15

Epithelial ovarian cancer (EOC) is a complex disease comprising discrete histological and molecular subtypes, for which survival r..

Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE)

A Talhouk, J George, C Wang, T Budden, TZ Tan, DS Chiu, S Kommoss, HS Leong, S Chen, MP Intermaggio, B Gilks, TM Nazeran, M Volchek, W Elatre, RC Bentley, J Senz, A Lum, V Chow, H Sudderuddin, R Mackenzie

2020-10-15

Purpose: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple s..

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

FC Martins, DL Couturier, A Paterson, AN Karnezis, C Chow, TM Nazeran, A Odunsi, A Gentry-Maharaj, A Vrvilo, A Hein, A Talhouk, A Osorio, AD Hartkopf, A Brooks-Wilson, A DeFazio, A Fischer, A Hartmann, BY Hernandez, BM McCauley, C Karpinskyj

2020-09-01

Background: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear ..

Prognostic gene expression signature for high-grade serous ovarian cancer

J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, MP Intermaggio, HS Leong, S Chen, W Elatre, B Gilks, T Nazeran, M Volchek, RC Bentley, C Wang, DS Chiu, S Kommoss, SCY Leung, J Senz, A Lum, V Chow

2020-09-01

Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies ..

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

NS Meagher, L Wang, PF Rambau, MP Intermaggio, DG Huntsman, LR Wilkens, MA El-Bahrawy, RB Ness, K Odunsi, H Steed, E Herpel, MS Anglesio, B Zhang, N Lambie, AJ Swerdlow, J Lubiński, RA Vierkant, EL Goode, U Menon, A Toloczko-Grabarek

2019-12-01

Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The..

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

M Tang, RL O'Connell, F Amant, P Beale, O McNally, KM Sjoquist, P Grant, A Davis, P Sykes, L Mileshkin, T Moujaber, CJ Kennedy, A deFazio, K Tan, Y Antill, J Goh, T Bonaventura, J Scurry, M Friedlander

2019-09-01

Objective: Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borde..

Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk

Y Yang, L Wu, X Shu, Y Lu, XO Shu, Q Cai, A Beeghly-Fadiel, B Li, F Ye, A Berchuck, H Anton-Culver, S Banerjee, J Benitez, L Bjørge, JD Brenton, R Butzow, IG Campbell, J Chang-Claude, K Chen, LS Cook

2019-02-01

DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark..

Accelerated Barocycler Lysis and Extraction Sample Preparation for Clinical Proteomics by Mass Spectrometry

N Lucas, AB Robinson, M Marcker Espersen, S Mahboob, D Xavier, J Xue, RL Balleine, A Defazio, PG Hains, PJ Robinson

2019-01-04

We have developed a streamlined proteomic sample preparation protocol termed Accelerated Barocycler Lysis and Extraction (ABLE) th..

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

PF Rambau, RA Vierkant, MP Intermaggio, LE Kelemen, MT Goodman, E Herpel, PD Pharoah, S Kommoss, M Jimenez-Linan, BY Karlan, A Gentry-Maharaj, U Menon, SH Polo, FJ Candido Dos Reis, JA Doherty, SA Gayther, R Sharma, MC Larson, PR Harnett, E Hatfield

2018-10-01

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it..

A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk

Y Lu, A Beeghly-Fadiel, L Wu, X Guo, B Li, JM Schildkraut, HK Im, YA Chen, JB Permuth, BM Reid, JK Teer, KB Moysich, IL Andrulis, H Anton-Culver, BK Arun, EV Bandera, RB Barkardottir, DR Barnes, J Benitez, L Bjorge

2018-09-15

Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer..

Transducin-Like enhancer of split 3 (TLE3) expression is associated with taxane sensitivity in nonserous ovarian carcinoma in a three-Cohort study

BZ Ring, R Murali, RA Soslow, DDL Bowtell, S Fereday, A Defazio, N Traficante, CJ Kennedy, A Brand, R Sharma, P Harnett, G Samimi

2018-06-01

Background: Chemoresistance is a major challenge in ovarian cancer treatment, resulting in poor survival rates. Identifying marker..

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

MS Block, RA Vierkant, PF Rambau, SJ Winham, P Wagner, N Traficante, A Toloczko, DG Tiezzi, FA Taran, P Sinn, W Sieh, R Sharma, JH Rothstein, T Ramón y Cajal, L Paz-Ares, O Oszurek, S Orsulic, RB Ness, G Nelson, F Modugno

2018-03-01

Objective: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in rela..

Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer

DW Garsed, K Alsop, S Fereday, C Emmanuel, CJ Kennedy, D Etemadmoghadam, B Gao, V Gebski, V Gares, EL Christie, MCA Wouters, K Milne, J George, AM Patch, J Li, GM Arnau, T Semple, SR Gadipally, YE Chiew, J Hendley

2018-02-01

Purpose: Women with epithelial ovarian cancer generally have a poor prognosis; however, a subset of patients has an unexpected dra..

Dose-response association of CD8 tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer

EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, A Gentry-Maharaj, A Tołoczko, A Hein, AL Bouligny, A Jensen, A Osorio, AD Hartkopf, A Ryan, A Chudecka-Głaz, AM Magliocco, A Hartmann, AY Jung, B Gao, BY Hernandez

2017-12-01

IMPORTANCE Cytotoxic CD8⁺ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian can..

The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer

KA Dickson, AJ Cole, AJ Gill, A Clarkson, GB Gard, A Chou, CJ Kennedy, BR Henderson, S Fereday, N Traficante, K Alsop, DD Bowtell, A de Fazio, R Clifton-Bligh, DJ Marsh

2016-01-01

Enzymatic factors driving cancer-associated chromatin remodelling are of increasing interest as the role of the cancer epigenome i..

Whole-genome characterization of chemoresistant ovarian cancer

AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, S Fereday, K Nones, P Cowin, K Alsop, PJ Bailey, KS Kassahn, F Newell, MCJ Quinn, S Kazakoff, K Quek, C Wilhelm-Benartzi, E Curry, HS Leong, A Hamilton, L Mileshkin

2015-05-28

Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatm..

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival

LOB Baumbusch, AH Helland, YW Wang, KL Liestol, MES Schaner, RH Holm, D Etemadmoghadam, KA Alsop, PB Brown, G Mitchell, SF Fereday, AD DeFazio, DD Bowtell, GBK Kristensen, OCL Lingjaerde, AB Borresen-Dale

2013-01-01

Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent studies ha..

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin

PA Cowin, J George, S Fereday, E Loehrer, P Van Loo, C Cullinane, D Etemadmoghadam, S Ftouni, L Galletta, MS Anglesio, J Hendley, L Bowes, KE Sheppard, EL Christie, RB Pearson, PR Harnett, V Heinzelmann-Schwarz, M Friedlander, O McNally, M Quinn

2012-08-15

High-grade serous cancer (HGSC), the most common subtype of ovarian cancer, often becomes resistant to chemotherapy, leading to po..